FOXP3 and nasopharyngeal carcinoma: Treatment with tanshinone IIA decreases the expression of miR-125b, which targets the transcription factor foxp3 and suppresses caspase-1 and GSDMD-N expression, ultimately increasing pyroptosis and inhibiting the proliferation of nasopharyngeal carcinoma cells; however, the relationship between foxp3 and caspase-1/GSDMD is unclear (Wang Y. et al., 2021).